Cargando…
Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
BACKGROUND: Oral corticosteroids were used to control stable chronic obstructive pulmonary disease (COPD) decades ago. However, recent guidelines do not recommend long-term oral corticosteroids (LTOC) use for stable COPD patients, partly because it causes side-effects such as respiratory muscle dete...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976535/ https://www.ncbi.nlm.nih.gov/pubmed/24708443 http://dx.doi.org/10.1186/1465-9921-15-37 |
_version_ | 1782310306598354944 |
---|---|
author | Horita, Nobuyuki Miyazawa, Naoki Morita, Satoshi Kojima, Ryota Inoue, Miyo Ishigatsubo, Yoshiaki Kaneko, Takeshi |
author_facet | Horita, Nobuyuki Miyazawa, Naoki Morita, Satoshi Kojima, Ryota Inoue, Miyo Ishigatsubo, Yoshiaki Kaneko, Takeshi |
author_sort | Horita, Nobuyuki |
collection | PubMed |
description | BACKGROUND: Oral corticosteroids were used to control stable chronic obstructive pulmonary disease (COPD) decades ago. However, recent guidelines do not recommend long-term oral corticosteroids (LTOC) use for stable COPD patients, partly because it causes side-effects such as respiratory muscle deterioration and immunosuppression. Nonetheless, the impact of LTOC on life prognosis for stable COPD patients has not been clarified. METHODS: We used the data of patients randomized to non-surgery treatment in the National Emphysema Treatment Trial. Severe and very severe stable COPD patients who were eligible for volume reduction surgery were recruited at 17 clinical centers in the United States and randomized during 1998-2002. Patients were followed-up for at least five years. Hazard ratios for death by LTOC were estimated by three models using Cox proportional hazard analysis and propensity score matching. RESULTS: The pre-matching cohort comprised 444 patients (prescription of LTOC: 23.0%. Age: 66.6 ± 5.4 year old. Female: 35.6%. Percent predicted forced expiratory volume in one second: 27.0 ± 7.1%. Mortality during follow-up: 67.1%). Hazard ratio using a multiple-variable Cox model in the pre-matching cohort was 1.54 (P = 0.001). Propensity score matching was conducted with 26 parameters (C-statics: 0.73). The propensity-matched cohort comprised of 65 LTOC(+) cases and 195 LTOC(−) cases (prescription of LTOC: 25.0%. Age: 66.5 ± 5.3 year old. Female: 35.4%. Percent predicted forced expiratory volume in one second: 26.1 ± 6.8%. Mortality during follow-up: 71.3%). No parameters differed between cohorts. The hazard ratio using a single-variable Cox model in the propensity-score-matched cohort was 1.50 (P = 0.013). The hazard ratio using a multiple-variable Cox model in the propensity-score-matched cohort was 1.73 (P = 0.001). CONCLUSIONS: LTOC may increase the mortality of stable severe and very severe COPD patients. |
format | Online Article Text |
id | pubmed-3976535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39765352014-04-06 Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease Horita, Nobuyuki Miyazawa, Naoki Morita, Satoshi Kojima, Ryota Inoue, Miyo Ishigatsubo, Yoshiaki Kaneko, Takeshi Respir Res Research BACKGROUND: Oral corticosteroids were used to control stable chronic obstructive pulmonary disease (COPD) decades ago. However, recent guidelines do not recommend long-term oral corticosteroids (LTOC) use for stable COPD patients, partly because it causes side-effects such as respiratory muscle deterioration and immunosuppression. Nonetheless, the impact of LTOC on life prognosis for stable COPD patients has not been clarified. METHODS: We used the data of patients randomized to non-surgery treatment in the National Emphysema Treatment Trial. Severe and very severe stable COPD patients who were eligible for volume reduction surgery were recruited at 17 clinical centers in the United States and randomized during 1998-2002. Patients were followed-up for at least five years. Hazard ratios for death by LTOC were estimated by three models using Cox proportional hazard analysis and propensity score matching. RESULTS: The pre-matching cohort comprised 444 patients (prescription of LTOC: 23.0%. Age: 66.6 ± 5.4 year old. Female: 35.6%. Percent predicted forced expiratory volume in one second: 27.0 ± 7.1%. Mortality during follow-up: 67.1%). Hazard ratio using a multiple-variable Cox model in the pre-matching cohort was 1.54 (P = 0.001). Propensity score matching was conducted with 26 parameters (C-statics: 0.73). The propensity-matched cohort comprised of 65 LTOC(+) cases and 195 LTOC(−) cases (prescription of LTOC: 25.0%. Age: 66.5 ± 5.3 year old. Female: 35.4%. Percent predicted forced expiratory volume in one second: 26.1 ± 6.8%. Mortality during follow-up: 71.3%). No parameters differed between cohorts. The hazard ratio using a single-variable Cox model in the propensity-score-matched cohort was 1.50 (P = 0.013). The hazard ratio using a multiple-variable Cox model in the propensity-score-matched cohort was 1.73 (P = 0.001). CONCLUSIONS: LTOC may increase the mortality of stable severe and very severe COPD patients. BioMed Central 2014 2014-04-03 /pmc/articles/PMC3976535/ /pubmed/24708443 http://dx.doi.org/10.1186/1465-9921-15-37 Text en Copyright © 2014 Horita et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Horita, Nobuyuki Miyazawa, Naoki Morita, Satoshi Kojima, Ryota Inoue, Miyo Ishigatsubo, Yoshiaki Kaneko, Takeshi Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease |
title | Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease |
title_full | Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease |
title_fullStr | Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease |
title_full_unstemmed | Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease |
title_short | Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease |
title_sort | evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976535/ https://www.ncbi.nlm.nih.gov/pubmed/24708443 http://dx.doi.org/10.1186/1465-9921-15-37 |
work_keys_str_mv | AT horitanobuyuki evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease AT miyazawanaoki evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease AT moritasatoshi evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease AT kojimaryota evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease AT inouemiyo evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease AT ishigatsuboyoshiaki evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease AT kanekotakeshi evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease |